Multicentric retrospective prognostic evaluation of tumor volumes and their alteration in the curative-intended radiotherapy of the locally advanced NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011342

Enrollment

700

Registered

2016-11-24

Start date

2017-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: CT-based (if available PET- or PET-CT-based) detection of macroscopic tumor volume (GTV1) prior to irradiation (basal GTV) as well as tumor volume changes during radiotherapy (volume increase

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • histologically confirmed NSCLC (Adeno / PLECA) stage UICC III A or B • Age> = 18 years • complete curative-intended radiotherapy (± chemotherapy), normofraction (achieved total dose =60 Gy) or hypofraction (=50 Gy)

Exclusion criteria

Exclusion criteria: •Stereotactic radiotherapy •Second malignancy <5 years before diagnosis of NSCLC •Pleural effusion, extensive atelectasis •Neoadjuvant chemotherapy before RT

Design outcomes

Primary

Measure	Time frame
Gross tumor volume (GTV basal, before radiotherapy)	—

Secondary

Measure	Time frame
Overall Survival	—

Countries

Germany, Switzerland

Contacts

Public ContactChristian Ostheimer

Klinik für Strahlentherapie und Radioonkologie Halle

christian.ostheimer@uk-halle.de(0345) 557 4310

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026